[Analysis of the Effcacy and Safety of Amivantamab in Non-small Cell Lung Cancer 
Patients with EGFR/MET Gene Abnormalities: A Single Center's Experience].

医学 肺癌 表皮生长因子受体 内科学 不利影响 肿瘤科 进行性疾病 癌症 奥西默替尼 癌症研究 疾病 埃罗替尼
作者
Jingjing Wang,Yujia Chi,Hanxiao Chen,Bo Jia,Xiaoyu Zhai,Menglei Ma,Jianjie Li,Minglei Zhuo
出处
期刊:DOAJ: Directory of Open Access Journals - DOAJ 卷期号:25 (7): 493-500 被引量:1
标识
DOI:10.3779/j.issn.1009-3419.2022.102.26
摘要

Epidermal growth factor receptor (EGFR) and cellular-mesenchymal to epithelial transition factor (c-Met) are widely expressed on cancer cells. There is a synergistic effect of EGFR and HGF/c-Met pathways on proliferation, downstream activation of signal transduction and an additive effect. Studies show that combination of both signaling pathways could potentially be targeted in a synergistic fashion. Amivantamab, a bispecific monoclonal antibody targeting EGFR and c-Met, yielded robust and durable responses in a variety of clinicals trials. However, few researches have reported its efficacy in Chinese non-small cell lung cancer (NSCLC) patients. This study was conducted to evaluate the effectiveness and tolerance of Amivantamab in NSCLC patients with EGFR/MET gene abnormalities at Peking University Cancer Hospital.The study enrolled NSCLC patients who received Amivantamab in our hospital between August 2020 and December 2021, and analyzed the response, survival, and treatment-related adverse events.Fifteen patients were enrolled in this research, and six of them received Amivantamab treatment and the other nine patients received Amivantamab plus Lazertinib treatment. The rates of partial response (PR), stable disease (SD), and progressive disease (PD) were 46.7% (7/15), 46.7% (7/15) and 6.7% (1/15), respectively. The overall response rate (ORR) and disease control rate (DCR) were 28.6% (2/7) and 100.0% (7/7) in seven patients with EGFR exon 20 insertion, respectively. The ORR and DCR were 40.0% (2/5) and 100.0% (5/5) in five post-osimertinib EGFR-mutant patients, respectively. After a median follow-up of 8.7 months, the median progression-free survival and overall survival were not reached. The most common treatment-related adverse events were rash (86.7%), paronychia (80.0%), and infusion-related reactions (60.0%), and most of them were graded as 1 to 2. Grade 3 to 4 adverse events included rash (33.3%), alanine aminotransferase elevation (13.3%), gamma-glutamyl transpeptidase elevation (13.3%), peripheral edema (6.7%), thromboembolism (6.7%), interstitial lung disease (6.7%), and thrombocytopenia (6.7%).Amivantamab was effective in Chinese NSCLC patients with EGFR exon 20 insertion and post-Osimertinib EGFR-mutant patients, similar to the results of clinical trials conducted in western countries. Amivantamab was well tolerated and emphases should be put on adverse events such as rash, paronychia, and infusion-related reactions.【中文题目:Amivantamab治疗EGFR/MET基因异常 非小细胞肺癌的单中心经验】 【中文摘要:背景与目的 表皮生长因子受体(epidermal growth factor receptor, EGFR)和细胞间质上皮转换因子(cellular-mesenchymal to epithelial transition factor, c-Met)是非小细胞肺癌(non-small cell lung cancer, NSCLC)中常见的变异基因,都是受体酪氨酸激酶,在下游信号转导方面具有协同作用。针对EGFR和c-Met通路的靶向药物联合应用后,能够阻断PI3K/AKT/mTOR途径和Ras/Raf/Mek途径,限制补偿通路激活,发挥抗肿瘤作用。以Amivantamab为代表的EGFR和c-Met双特异性抗体新型药物能同时阻断两条信号通路,在肺癌临床研究中展现出良好前景。然而目前国内应用较少,相关经验缺乏。本研究将介绍我中心Amivantamab疗效数据和不良反应处理经验,探讨此类药物对我国EGFR/MET基因异常NSCLC的应用价值。方法 收集2020年8月-2021年12月于我院接受Amivantamab治疗的晚期NSCLC病例的临床数据,分析其治疗反应率、生存和不良反应。结果 本研究共纳入15例患者,其中Amivantamab单药治疗6例,Amivantamab联合Lazertinib治疗9例。治疗后7例(46.7%)达部分缓解(partial response, PR),7例(46.7%)达疾病稳定(stable disease, SD),1例(6.7%)达疾病进展(progressive disease, PD),总体客观缓解率(objective response rate, ORR)为46.7%,总体疾病控制率(disease control rate, DCR)为93.3%。7例EGFR外显子20插入突变患者中,2例(28.6%)达PR,5例(71.4%)达SD,DCR为100.0%,中位缓解持续时间(duration of response, DOR)未成熟,2例PR者仍持续缓解。5例奥希替尼耐药的患者中,2例(40.0%)达PR,3例(60.0%)达SD,DCR为100.0%,中位DOR未成熟,1例PR者仍持续缓解。中位随访时间为8.7个月(0.9个月-18.6个月),截至最后一次随访,共有6例患者发生疾病进展,3例患者死亡,中位无进展生存期和中位总生存期未成熟。常见的不良事件为皮疹(86.7%),甲沟炎(80.0%)和输液反应(60.0%),多为1级-2级。3级及以上不良反应包括皮疹(33.3%),转氨酶升高(13.3%)、水肿(6.7%)、血栓栓塞(6.7%)、间质性肺炎(6.7%)和血小板减低(6.7%)。结论 Amivantamab对EGFR外显子20插入突变和奥希替尼耐药的中国晚期NSCLC治疗有效,与国外疗效数据相仿。整体安全性可耐受,需重点关注皮疹、甲沟炎、输液反应等不良反应。 】 【中文关键词:肺肿瘤;EGFR;MET;靶向治疗;Amivantamab】.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
NexusExplorer应助沟通亿心采纳,获得10
刚刚
顾矜应助123321采纳,获得10
刚刚
细心觅风完成签到,获得积分10
2秒前
铅笔995发布了新的文献求助20
2秒前
大个应助ryd采纳,获得10
2秒前
3秒前
Yi羿完成签到 ,获得积分10
4秒前
4秒前
6秒前
7秒前
xinlei2023完成签到,获得积分10
8秒前
耿大海发布了新的文献求助10
9秒前
yn发布了新的文献求助10
9秒前
长白发布了新的文献求助10
10秒前
今后应助铅笔995采纳,获得10
12秒前
cccong1210发布了新的文献求助30
12秒前
12秒前
学术小白完成签到,获得积分10
12秒前
Adam完成签到,获得积分10
13秒前
扁桃体不发言完成签到,获得积分10
13秒前
ye完成签到,获得积分10
14秒前
许起眸发布了新的文献求助10
15秒前
16秒前
18秒前
懒123完成签到,获得积分10
18秒前
可爱的函函应助一二一采纳,获得10
19秒前
萨特完成签到,获得积分10
19秒前
Ljy发布了新的文献求助10
20秒前
量子星尘发布了新的文献求助10
22秒前
22秒前
22秒前
希望天下0贩的0应助Elaine采纳,获得10
23秒前
一米阳光发布了新的文献求助10
23秒前
许雨青完成签到,获得积分20
23秒前
23秒前
千千完成签到,获得积分10
23秒前
小二郎应助phoenix001采纳,获得10
24秒前
天天快乐应助kanwenxian采纳,获得10
24秒前
24秒前
24秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Toward a Combinatorial Approach for the Prediction of IgG Half-Life and Clearance 500
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970008
求助须知:如何正确求助?哪些是违规求助? 3514711
关于积分的说明 11175563
捐赠科研通 3250077
什么是DOI,文献DOI怎么找? 1795198
邀请新用户注册赠送积分活动 875630
科研通“疑难数据库(出版商)”最低求助积分说明 804931